Moderna Q2 Revenue Misses, Norovirus Vaccine Fails Interim, but Cost Cuts Lift Cash Outlook
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna reported Q2 revenue of $145M and a net loss of $(0.8)B, while its norovirus vaccine candidate failed a Phase 3 interim analysis. The company improved its 2026 cost outlook and raised its year-end cash forecast, with a key FDA decision on its flu vaccine due August 5.
Updates
· Benzinga — Q2 loss was $1.97 per share, beating estimates. Cash on hand fell to $6.9B from $7.5B in March, with a $950M litigation payment made in July. Stock fell 2.7% after a 7.2% premarket drop.
· Dow Jones Newswires — Shares fell 7.2% premarket despite the beat. Moderna reiterated full-year guidance of 10% revenue growth, with 55% of H2 revenue expected in Q3. Spikevax sales were buoyed by UK deliveries, masking declines in the US and South America.
Key Events · Earnings and Guidance · MRNA
-
Q2 Revenue Misses Expectations
Revenue of $145 million was flat year-over-year and well below Q1's $389 million, driven by lower COVID vaccine sales in the U.S. and South America.
-
Norovirus Vaccine Fails Interim
mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis; the trial remains blinded and an additional cohort will be enrolled.
-
Cost Outlook Improves
2026 GAAP operating expense outlook reduced by ~$200 million; year-end cash balance now projected at $4.7–5.2 billion, up from prior estimate.
-
Flu Vaccine PDUFA on August 5
FDA decision on mFLUSIVA (mRNA-1010) expected August 5, 2026, following unanimous VRBPAC recommendation — potential fifth approved product.
Analysis · MRNA · Life Sciences
Second-quarter revenue of $145 million fell short of the $389 million reported in Q1, underscoring the lumpy nature of COVID vaccine sales. The bigger blow is the Phase 3 interim failure of its norovirus vaccine, mRNA-1403, which missed statistical criteria for early success — a setback for a pipeline that investors were counting on to diversify beyond COVID. On the positive side, management improved its 2026 operating expense outlook by roughly $200 million and raised its year-end cash forecast to $4.7–5.2 billion, signaling tighter cost control. The upcoming August 5 PDUFA date for its flu vaccine, mFLUSIVA, now carries even more weight as a potential fifth approved product.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRNA was trading at $55.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23B. The 52-week trading range was $22.28 to $85.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.